Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PSTC100 in Healthy Adult Subjects

NCT07752472 is registered in ClinicalTrials.gov with Prospect Therapeutics (Nanjing) Limited as lead sponsor.

NCT NCT07752472
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07752472 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PSTC100 in Healthy Adult Subjects
Lead sponsor
Prospect Therapeutics (Nanjing) Limited
Phase
Phase 1
Overall status
Recruiting
Start date
September 1, 2026
Completion date
October 10, 2027
Enrollment
70 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy adult subjects